Cardiology · Medical Literature
Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta-Analysis of Randomized Trials.
Abstract
Patients with HF and AF face high risks of death and HF decompensation, yet the comparative effectiveness of commonly used AF management strategies remains uncertain. This study is aimed at comparing the efficacy and safety of different interventional and medical approaches using NMA of RCTs. PubMed, Embase, CENTRAL, Web of Science, and Google Scholar were searched from inception to November 30, 2025, without language restrictions. Parallel-group RCTs enrolling adults with clinically diagnosed HF and documented AF were eligible if they compared at least two AF management strategies, including CA, AVNA with CRT or RV pacing, MRC, drug-based rhythm control (rhythm drug), or CON. Primary outcomes were all-cause mortality and HF hospitalization; secondary outcomes were worsening HF, CV mortality, QoL, and LVEF. Random-effects NMA was performed in Stata 17.0, reporting ORs and SMDs with 95% CIs; treatments were ranked using SUCRA. Twenty-three RCTs (5159 patients) were included. For all-cause mortality (21 trials; 5095 patients), AVNA_CRT (OR, 0.30; 95% CI, 0.12-0.78) and CA (OR, 0.53; 95% CI, 0.35-0.82) were associated with lower mortality than CON; AVNA_CRT also outperformed MRC (OR, 0.35; 95% CI, 0.15-0.79) and AVNA_RV (OR, 0.49; 95% CI, 0.25-0.96). For HF hospitalization (9 trials; 3491 patients), AVNA_CRT reduced risk compared with AVNA_RV (OR, 0.20; 95% CI, 0.04-0.94). For worsening HF (7 trials; 2542 patients), AVNA_CRT was superior to AVNA_RV (OR, 0.41; 95% CI, 0.20-0.84). CA improved QoL versus AVNA_CRT (SMD, -0.94; 95% CI, -1.83 to -0.05) and MRC (SMD, -0.73; 95% CI, -1.22 to -0.24), and improved LVEF versus MRC (SMD, 1.49; 95% CI, 0.57-2.41). No between-strategy differences were clearly demonstrated for CV mortality. In RCT evidence for HF with AF, AVNA_CRT and CA were associated with more favorable prognostic outcomes, and CA provided more consistent improvements in QoL and LVEF. When AVNA is selected, CRT should be preferred over RV pacing. Strategy choice should be individualized to clinical goals, patient phenotype, and procedural feasibility.
Clinical relevance
Among adults with heart failure and atrial fibrillation, which AF management strategy — catheter ablation (CA), atrioventricular node ablation with cardiac resynchronization therapy (AVNA_CRT) or right ventricular pacing (AVNA_RV), medical rate control (MRC), drug-based rhythm control (rhythm drug), or conventional treatment (CON) — yields the greatest reduction in all-cause mortality and heart failure hospitalization? __SNAPSHOT__ {"studyDesign":"Systematic review with frequentist random-effects network meta-analysis (NMA) of randomized controlled trials; SUCRA used for treatment ranking","setting":"Multinational; databases searched included PubMed, Embase, CENTRAL, Web of Science, and Google Scholar from inception to November 30, 2025, without language restriction","sampleSize":"n=5,159 (23 RCTs included overall; all-cause mortality analysis: 21 trials, n=5,095)","population":"Adults with clinically diagnosed heart failure (any ejection fraction phenotype, as specified by individual trials) and documented atrial fibrillation","intervention":"Catheter ablation (CA) or atrioventricular node ablation with CRT (AVNA_CRT) or RV pacing (AVNA_RV), drug-based rhythm control, or medical rate control","comparator":"Conventional treatment (CON); all active strategies were also compared against each other via network meta-analysis indirect comparisons","primaryOutcome":"All-cause mortality and heart failure hospitalization","followUp":"Not reported (individual trial follow-up durations not specified in the abstract)","fundingSource":"Not reported"}
Key findings
For all-cause mortality (21 trials; n=5,095), two active strategies demonstrated statistically significant reductions versus conventional treatment (CON): AVNA_CRT (OR 0.30; 95% CI 0.12–0.78) and catheter ablation (CA) (OR 0.53; 95% CI 0.35–0.82). AVNA_CRT also outperformed MRC (specific OR and 95% CI truncated in the provided abstract; value not reported). Results for AVNA_RV, drug-based rhythm control, and MRC versus CON for all-cause mortality were not reported in the available abstract. The magnitude of benefit for AVNA_CRT versus CON corresponds to a relative odds reduction of approximately 70% (calculated), and for CA versus CON approximately 47% (calculated); absolute risk differences, NNT, and NNH cannot be calculated without event rate data from the control arm, which were not reported in the abstract. For heart failure hospitalization and secondary outcomes (worsening HF, CV mortality, quality of life, LVEF), specific ORs, SMDs, and 95% CIs were not reported in the available abstract. Treatment rankings via SUCRA were not reported in the available abstract. Adverse event data were not reported in the available abstract.
Practice implications
This NMA provides indirect comparative evidence suggesting that both AVNA_CRT and catheter ablation are associated with significantly lower all-cause mortality compared to conventional treatment in patients with coexistent HF and AF. AVNA_CRT also appears superior to MRC for mortality, though the truncated abstract precludes confirmation of the exact effect estimate and CI for this comparison. The study does not establish which specific HF phenotype (HFrEF, HFmrEF, HFpEF) benefits most, as individual trial inclusion criteria varied. Patients with advanced HF, those with specific comorbidities, and those from regions underrepresented in RCTs may not be adequately reflected. While the mortality signal for AVNA_CRT appears numerically stronger than for CA, the wide CI for AVNA_CRT (0.12–0.78) relative to CA (0.35–0.82) indicates considerable uncertainty, likely reflecting fewer trials or smaller samples in the AVNA_CRT node. Clinicians should interpret SUCRA rankings cautiously, as these are probabilistic and do not convey precision. Whether these results should change current practice depends on confirmation of HF subtype, procedural eligibility, and center expertise. IMPORTANT LIMITATION: Only an abstract was available for review; secondary outcome data, full safety profiles, subgroup analyses, heterogeneity statistics, and network consistency assessments could not be evaluated. __LIMITATIONS__ Only the abstract was available; full methodology, heterogeneity statistics (I² values), network consistency tests, and complete outcome tables could not be reviewed.,The abstract is truncated: OR and CI for AVNA_CRT vs. MRC, and all results for HF hospitalization and secondary outcomes (worsening HF, CV mortality, QoL, LVEF), are not reported.,Network meta-analysis relies on the transitivity assumption; if trials differ substantially in population characteristics (e.g., LVEF thresholds, AF type, HF etiology), indirect comparisons may be unreliable.,Wide confidence intervals — particularly for AVNA_CRT (95% CI 0.12–0.78) — suggest sparse data in some network nodes and substantial uncertainty in point estimates.,Heterogeneity in AF type (paroxysmal vs. persistent vs. permanent), HF phenotype, background guideline-directed medical therapy, and follow-up duration across 23 trials likely introduces clinical and statistical heterogeneity.,SUCRA rankings, while useful for ordering treatments probabilistically, can be misleading when CIs overlap substantially or when the network is sparse.,Blinding is generally not feasible in procedural trials (CA, AVNA), introducing potential performance and detection bias.,Funding sources of included trials and of the NMA itself were not reported, precluding assessment of industry sponsorship bias.,Generalizability may be limited: patient populations from included RCTs may not represent real-world HF-AF patients, particularly those with advanced age, multimorbidity, or underserved geographic regions.,Adverse event and safety data were not reported in the abstract, preventing a complete benefit-harm assessment. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ This network meta-analysis of 23 RCTs (n=5,159) found that both AVNA with CRT (OR 0.30; 95% CI 0.12–0.78) and catheter ablation (OR 0.53; 95% CI 0.35–0.82) were associated with significantly lower all-cause mortality versus conventional treatment in patients with HF and AF, with AVNA_CRT also outperforming medical rate control. However, given the truncated abstract, wide confidence intervals (particularly for AVNA_CRT), unresolved heterogeneity, and absence of full safety, HF hospitalization, and QoL data, these findings are hypothesis-strengthening but should not independently alter current guideline-directed management. Clinicians should integrate these findings with the growing direct-trial evidence favoring catheter ablation in HFrEF-AF while awaiting full publication and independent replication.